Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2 that undergoes cleavage by histone B within tumor cells, thereby achieving selective targeting of these cells. It exhibits antitumor activity and is applicable in cancer research, particularly concerning uterine and ovarian sarcomas [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2 that undergoes cleavage by histone B within tumor cells, thereby achieving selective targeting of these cells. It exhibits antitumor activity and is applicable in cancer research, particularly concerning uterine and ovarian sarcomas [1]. |
In vitro | Trastuzumab duocarmazine (SYD985) displayed cytotoxic activity against both HER2-negative and HER2-positive cell lines at concentrations ranging from 0.0001 to 100 μg/mL over a 24-hour period. It was seven times more potent against HER2/NEU 3+ cell lines, with an IC50 value of 0.013 μg/mL, compared to T-DM1, which had an IC50 value of 0.096 μg/mL. Notably, in HER2/NEU 1+ cells, the potency of SYD985 was 54 times higher than that of T-DM1 [1]. |
In vivo | Trastuzumab duocarmazine (SYD985) administered intravenously at doses of 3 mg/kg or 10 mg/kg significantly inhibited tumor growth and prolonged survival in mice, demonstrating potent in vivo antitumor activity [1]. |
Synonyms | (vic)-Trastuzumab duocarmazine |
Molecular Weight | N/A |
CAS No. | 1642152-40-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Trastuzumab duocarmazine 1642152-40-6 (vic)-Trastuzumab duocarmazine inhibitor inhibit